Iovance Biotherapeutics, Inc.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a pioneering biotechnology company focused on the development and commercialization of innovative cell therapy products for cancer treatment. The company is dedicated to harnessing the power of the immune system to fight cancer through its proprietary tumour-infiltrating lymphocyte (TIL) therapy. Iovance’s lead product candidate, lifileucel, is designed to provide patients with personalised treatment options that are tailored to their specific tumour characteristics.

Founded with a vision to transform cancer care, Iovance aims to improve patient outcomes by offering therapies that are not only effective but also accessible. The company operates from its state-of-the-art facilities, where it conducts extensive research and development to advance its therapeutic pipeline. Iovance is committed to adhering to the highest standards of quality and safety in its manufacturing processes.

• Core Activities: Development of TIL therapy, clinical trials, and regulatory submissions.
• Vision: To revolutionise cancer treatment through innovative cell therapies.
• Commitment: Ensuring patient-centric approaches in all aspects of its operations.

With a robust pipeline of clinical programs, Iovance is actively engaged in collaborations with leading research institutions and healthcare providers. The company believes in the potential of personalised medicine and strives to bring hope to patients battling cancer. As Iovance continues to grow, it remains focused on its mission to deliver transformative therapies that can change the landscape of cancer treatment.